Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase

Romy Perez-Abraham, Karla Garabiles Sanchez, Melany Alfonso, Ueli Gubler, John Siekierka, Nina Goodey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Brugia malayi (B. malayi) is one of the three causative agents of lymphatic filariasis, a neglected parasitic disease. Current literature suggests that dihydrofolate reductase is a potential drug target for the elimination of B. malayi. Here we report the recombinant expression and purification of a ∼20 kDa B. malayi dihydrofolate reductase (BmDHFR). A His6-tagged construct was expressed in E. coli and purified by affinity chromatography to yield active and homogeneous enzyme for steady-state kinetic characterization and inhibition studies. The catalytic activity kcat was found to be 1.4 ± 0.1 s−1, the Michaelis Menten constant KM for dihydrofolate 14.7 ± 3.6 μM, and the equilibrium dissociation constant KD for NADPH 25 ± 24 nM. For BmDHFR, IC50 values for a six DHFR inhibitors were determined to be 3.1 ± 0.2 nM for methotrexate, 32 ± 22 μM for trimethoprim, 109 ± 34 μM for pyrimethamine, 154 ± 46 μM for 2,4-diaminoquinazoline, 771 ± 44 μM for cycloguanil, and >20,000 μM for 2,4-diaminopyrimidine. Our findings suggest that antifolate compounds can serve as inhibitors of BmDHFR.

Original languageEnglish
Pages (from-to)81-85
Number of pages5
JournalProtein Expression and Purification
Volume128
DOIs
StatePublished - 1 Dec 2016

Fingerprint

Brugia malayi
Tetrahydrofolate Dehydrogenase
Neglected Diseases
Filarial Elephantiasis
Folic Acid Antagonists
Pyrimethamine
Parasitic Diseases
Trimethoprim
NADP
Affinity Chromatography
Methotrexate
Inhibitory Concentration 50
Escherichia coli
Enzymes
Pharmaceutical Preparations
2,4-diaminoquinazoline
cycloguanil
dihydrofolate
2,4-diaminopyrimidine

Keywords

  • Antifolate inhibitors
  • Brugia malayi
  • Dihydrofolate reductase
  • Filariasis
  • Steady-state kinetics

Cite this

Perez-Abraham, Romy ; Sanchez, Karla Garabiles ; Alfonso, Melany ; Gubler, Ueli ; Siekierka, John ; Goodey, Nina. / Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase. In: Protein Expression and Purification. 2016 ; Vol. 128. pp. 81-85.
@article{25ec463d6e3941c8b049eef732f4cdd6,
title = "Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase",
abstract = "Brugia malayi (B. malayi) is one of the three causative agents of lymphatic filariasis, a neglected parasitic disease. Current literature suggests that dihydrofolate reductase is a potential drug target for the elimination of B. malayi. Here we report the recombinant expression and purification of a ∼20 kDa B. malayi dihydrofolate reductase (BmDHFR). A His6-tagged construct was expressed in E. coli and purified by affinity chromatography to yield active and homogeneous enzyme for steady-state kinetic characterization and inhibition studies. The catalytic activity kcat was found to be 1.4 ± 0.1 s−1, the Michaelis Menten constant KM for dihydrofolate 14.7 ± 3.6 μM, and the equilibrium dissociation constant KD for NADPH 25 ± 24 nM. For BmDHFR, IC50 values for a six DHFR inhibitors were determined to be 3.1 ± 0.2 nM for methotrexate, 32 ± 22 μM for trimethoprim, 109 ± 34 μM for pyrimethamine, 154 ± 46 μM for 2,4-diaminoquinazoline, 771 ± 44 μM for cycloguanil, and >20,000 μM for 2,4-diaminopyrimidine. Our findings suggest that antifolate compounds can serve as inhibitors of BmDHFR.",
keywords = "Antifolate inhibitors, Brugia malayi, Dihydrofolate reductase, Filariasis, Steady-state kinetics",
author = "Romy Perez-Abraham and Sanchez, {Karla Garabiles} and Melany Alfonso and Ueli Gubler and John Siekierka and Nina Goodey",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.pep.2016.08.012",
language = "English",
volume = "128",
pages = "81--85",
journal = "Protein Expression and Purification",
issn = "1046-5928",
publisher = "Academic Press Inc.",

}

Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase. / Perez-Abraham, Romy; Sanchez, Karla Garabiles; Alfonso, Melany; Gubler, Ueli; Siekierka, John; Goodey, Nina.

In: Protein Expression and Purification, Vol. 128, 01.12.2016, p. 81-85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase

AU - Perez-Abraham, Romy

AU - Sanchez, Karla Garabiles

AU - Alfonso, Melany

AU - Gubler, Ueli

AU - Siekierka, John

AU - Goodey, Nina

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Brugia malayi (B. malayi) is one of the three causative agents of lymphatic filariasis, a neglected parasitic disease. Current literature suggests that dihydrofolate reductase is a potential drug target for the elimination of B. malayi. Here we report the recombinant expression and purification of a ∼20 kDa B. malayi dihydrofolate reductase (BmDHFR). A His6-tagged construct was expressed in E. coli and purified by affinity chromatography to yield active and homogeneous enzyme for steady-state kinetic characterization and inhibition studies. The catalytic activity kcat was found to be 1.4 ± 0.1 s−1, the Michaelis Menten constant KM for dihydrofolate 14.7 ± 3.6 μM, and the equilibrium dissociation constant KD for NADPH 25 ± 24 nM. For BmDHFR, IC50 values for a six DHFR inhibitors were determined to be 3.1 ± 0.2 nM for methotrexate, 32 ± 22 μM for trimethoprim, 109 ± 34 μM for pyrimethamine, 154 ± 46 μM for 2,4-diaminoquinazoline, 771 ± 44 μM for cycloguanil, and >20,000 μM for 2,4-diaminopyrimidine. Our findings suggest that antifolate compounds can serve as inhibitors of BmDHFR.

AB - Brugia malayi (B. malayi) is one of the three causative agents of lymphatic filariasis, a neglected parasitic disease. Current literature suggests that dihydrofolate reductase is a potential drug target for the elimination of B. malayi. Here we report the recombinant expression and purification of a ∼20 kDa B. malayi dihydrofolate reductase (BmDHFR). A His6-tagged construct was expressed in E. coli and purified by affinity chromatography to yield active and homogeneous enzyme for steady-state kinetic characterization and inhibition studies. The catalytic activity kcat was found to be 1.4 ± 0.1 s−1, the Michaelis Menten constant KM for dihydrofolate 14.7 ± 3.6 μM, and the equilibrium dissociation constant KD for NADPH 25 ± 24 nM. For BmDHFR, IC50 values for a six DHFR inhibitors were determined to be 3.1 ± 0.2 nM for methotrexate, 32 ± 22 μM for trimethoprim, 109 ± 34 μM for pyrimethamine, 154 ± 46 μM for 2,4-diaminoquinazoline, 771 ± 44 μM for cycloguanil, and >20,000 μM for 2,4-diaminopyrimidine. Our findings suggest that antifolate compounds can serve as inhibitors of BmDHFR.

KW - Antifolate inhibitors

KW - Brugia malayi

KW - Dihydrofolate reductase

KW - Filariasis

KW - Steady-state kinetics

UR - http://www.scopus.com/inward/record.url?scp=84983385721&partnerID=8YFLogxK

U2 - 10.1016/j.pep.2016.08.012

DO - 10.1016/j.pep.2016.08.012

M3 - Article

C2 - 27544923

AN - SCOPUS:84983385721

VL - 128

SP - 81

EP - 85

JO - Protein Expression and Purification

JF - Protein Expression and Purification

SN - 1046-5928

ER -